Silence Therapeutics (SLN) | Stock Overview & Key Data
Silence Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $4.81
High: $5.29
on August 29, 2025
52 Week Range
Low: $1.97
High: $20.48
on April 10, 2025
on October 9, 2024
All-Time High: $35.00 on May 24, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$244.2M
EPS
-1.68
P/E Ratio (TTM)
-5.15
Forward P/E
-6.80
P/B Ratio
2.59
PEG Ratio
-0.15
Div. Yield
N/A
ROE
-66.96%
Beta
1.390
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
62.05%
Operating Margin
-9,048.21%
Profit Margin
-291.24%
Returns and Earnings
Return on Assets (TTM)
-22.25%
Return on Equity (TTM)
-66.96%
EBITDA
$-71.3M
Net Income (TTM)
$-79.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.19
Quarterly Revenue Growth (YoY)
-70.40%
Quarterly Earnings Growth (YoY)
-70.38%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Silence Therapeutics SLN | 244.20M Micro-cap | -10.09% | -22.42% | -19.02% | 6.89% | -33.10% | -74.80% | -54.58% | -75.33% |
| Vertex VRTX | 99.55B Large-cap | -1.04% | -16.52% | -12.54% | -18.50% | -3.63% | -21.15% | 39.13% | 46.72% |
| Regeneron REGN | 62.21B Large-cap | -1.49% | 4.04% | -4.08% | -16.89% | -18.80% | -50.98% | 0.01% | 0.06% |
| Editas Medicine EDIT | 231.09M Micro-cap | -8.21% | -0.77% | 40.44% | 33.85% | 96.18% | -31.28% | -82.67% | -91.57% |
| Alector ALEC | 237.85M Micro-cap | -6.75% | 45.96% | 65.49% | 43.29% | 24.34% | -55.49% | -77.53% | -81.06% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
Ownership & Short Interest
Insider Ownership
24.38%
Institutional Ownership
44.25%
Shares Short
770K
Short Ratio
9.84
Short % of Shares Outstanding
2.06%
Average 10-Day Volume
46K
Average 90-Day Volume
66K
Silence Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Silence Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SLN's 52-week high and low?
- In the last 52 weeks, Silence Therapeutics reached a high of $20.48 (on October 9, 2024) and a low of $1.97 (on April 10, 2025).
- What is the market cap and P/E ratio for SLN?
- Curious about Silence Therapeutics's size and valuation? Its market capitalization stands at 244.20M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.15, and the forward P/E (looking ahead) is -6.80.
- Does SLN pay dividends? If so, what's the yield?
- As for dividends, Silence Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Silence Therapeutics's main competitors or similar companies to consider before investing?
When looking at Silence Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX99.55B Healthcare Biotechnology -21.15% 39.13% Regeneron
REGN62.21B Healthcare Biotechnology -50.98% 0.01% Editas Medicine
EDIT231.09M Healthcare Biotechnology -31.28% -82.67% Alector
ALEC237.85M Healthcare Biotechnology -55.49% -77.53% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Silence Therapeutics plc ADR? (e.g., ROE, Debt/Equity)
- To get a sense of Silence Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -66.96%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 62.05%.
- What is the recent revenue and earnings growth for SLN?
- Looking at Silence Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $27M. Compared to the same quarter last year (YoY), quarterly revenue grew by -70.40%, and quarterly earnings saw a YoY growth of -70.38%.
- How much of SLN stock is held by insiders and institutions?
- Wondering who owns Silence Therapeutics stock? Company insiders (like executives and directors) hold about 24.38% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 44.25%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.